High-Dose Therapy and Autologous Hematopoietic Progenitor Cells Transplantation for Recurrent or Refractory Hodgkin's Lymphoma: Analysis of King Hussein Cancer Center Results and Prognostic Variables

Table 1

Characteristics of 63 patients with HL who underwent autologous stem cell transplantation.

		Count (%)
Gender	Male	38 (60.3%)
	Female	25 (39.7%)
Age	Adult	54 (85.7%)
	Pediatric	9 (14.3%)
Number of previous Chemotherapy lines received	2 lines	35 (55.6%)
	>2 lines	28 (44.4%)
Disease status at transplant	Complete remission	16 (25.4%)
	Responsive disease	45 (71.4%)
	Stable disease	2 (3.2%)
Time to relapse (TTR)	≤12 months	30 (48%)
	>12 months	33 (52%)
Mobilization regimen	Chemotherapy + GCSF	57 (90.5%)
	GCSF only	6 (9.5%)
Stem cell source	Peripheral	63 (100%)
Stem cell dose	Median (range)	5.6 × 10^6/kg
		(1.51−12.1 × 10^6/kg)
Conditioning regimen	BEAM*	60 (95.2%)
	TEAM**	2 (3.2%)
	CBV***	1 (1.6%)

*BEAM: BCNU, etoposide, Ara-C, melphalan.
**TEAM: thiotepa, etoposide, Ara-C, melphalan.
***CBV: cyclophosphamide, BCNU, VP16.